三生製藥(01530.HK):Ampholipad™上市申請獲國家藥監局受理
格隆匯 8 月 26日丨三生製藥(01530.HK)公告,內容有關TLC的Ampholipad™上市申請(MAA)已獲得國家藥品監督管理局受理,該產品為吉利德公司AmBisome®(兩性黴素B脂質體注射劑)的化學仿製藥,用於治療全身真菌感染。TLC是一家臨牀階段製藥公司,於納斯達克及台灣證券櫃枱買賣中心雙重上市(納斯達克:TLC,TWO:4152),並且是公司的合作伙伴。公司將在中國大陸將該產品商業化。
公告乃由公司自願刊發。集團無法保證Ampholipad™將成功或最終於中國大陸推出。公司股東及潛在投資者在買賣公司股份時務請審慎行事。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.